Results 21 to 30 of about 22,351 (243)
Neurology: Neuroimmunology & Neuroinflammation, 2023 Background and Objectives Inflammasomes are involved in the pathogenesis of different neuroimmune and neurodegenerative diseases, including multiple sclerosis (MS).
S. Malhotra +7 more
semanticscholar +1 more source
Exploratory Research in Clinical and Social Pharmacy, 2021 Background: Fingolimod is the first approved oral disease-modifying agent (DMA) in 2010 to treat Multiple Sclerosis (MS). There is limited real-world evidence regarding the determinants associated with fingolimod use in the early years.
Jagadeswara Rao Earla +5 more
doaj +1 more source
Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy
Neurology: Neuroimmunology & Neuroinflammation, 2023 Background and Objective Discontinuation of fingolimod ≥2 months before pregnancy is recommended to minimize potential teratogenicity. The magnitude of MS pregnancy relapse risk, particularly severe relapses, after fingolimod cessation is unclear, as is ...
K. Hellwig +7 more
semanticscholar +1 more source
Time- and Sex-Dependent Effects of Fingolimod Treatment in a Mouse Model of Alzheimer’s Disease
Biomolecules, 2023 Alzheimer’s disease (AD) is the most common cause of dementia. Fingolimod has previously shown beneficial effects in different animal models of AD. However, it has shown contradictory effects when it has been applied at early disease stages.
P. Bascuñana +7 more
semanticscholar +1 more source
, 2022 Charge-altering releasable transporters (CARTs) are a class of oligonucleotide delivery vehicles shown to be effective for delivery of messenger RNA (mRNA) both in vitro and in vivo.
Paul A. Wender (1321791) +8 more
core +1 more source
Fingolimod Promotes Antibacterial Effect of Doripenem against Carbapenem-Resistant Escherichia coli
Antibiotics, 2022 The aim of this study was to determine whether fingolimod could synergize the antibacterial activity of doripenem against carbapenem-resistant Escherichia coli (CREC) and its potential as an antibiotic adjuvant for doripenem. The E.
Hye-Won Jin, Hye-Rim Kim, Yong-Bin Eom
doaj +1 more source
Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models
Cancers, 2023 Simple Summary Grade 4 gliomas and glioblastomas are the most common brain tumors, accounting for 50% of primary brain tumors, and the most aggressive, with a median 5-year patient survival of less than 10%.
M. Davy +6 more
semanticscholar +1 more source
Journal of Neuroinflammation, 2023 Background Multiple sclerosis (MS) is a disabling autoimmune demyelinating disorder affecting young people and causing significant disability. In the last decade, different microRNA (miRNA) expression patterns have been associated to several treatment ...
Alicia González-Martínez +8 more
semanticscholar +1 more source
Fingolimod modulates microglial activation to augment markers of remyelination [PDF]
, 2011 Introduction Microglial activation in multiple sclerosis has been postulated to contribute to long-term neurodegeneration during disease. Fingolimod has been shown to impact on the relapsing remitting phase of disease by modulating autoreactive T-cell ...
Giovannoni Gavin +8 more
core +1 more source
Neurotherapeutics, 2023 Obesity is considered a risk factor for type 2 diabetes mellitus, which has become one of the most important health problems, and is also linked with memory and executive function decline.
P. Wencel +5 more
semanticscholar +1 more source